ARS Pharma's EURneffy Gains EU Pediatric Expansion: A Strategic Win, But Investor Caution Remains
ARS Pharmaceuticals secures a key European regulatory nod to expand its needle-free anaphylaxis spray, EURneffy, to younger children. While this bolsters the company's franchise, analysts highlight that core challenges of cash burn and market adoption persist, keeping investor sentiment mixed.